Logo image
Back
Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
Journal article   Open access   Peer reviewed

Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease

Aakash Desai, Jessica Petrov, Jana G Hashash, Harsh Patel, Bhaumik Brahmbhatt, Gursimran S Kochhar and Francis A Farraye
Alimentary pharmacology & therapeutics, v 60(5), pp 620-632
Sep 2024
DOI: https://doi.org/10.1111/apt.18138
PMID: 38938071
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1111/apt.18138View
Published, Version of Record (VoR) Open

Abstract

Adult Aged Colitis, Ulcerative - drug therapy Colitis, Ulcerative - surgery Crohn Disease - drug therapy Crohn Disease - surgery Diabetes Mellitus, Type 2 - drug therapy Female Glucagon-Like Peptide-1 Receptor Agonists Hospitalization - statistics & numerical data Humans Hypoglycemic Agents - therapeutic use Inflammatory Bowel Diseases - drug therapy Male Middle Aged Retrospective Studies Treatment Outcome Diabetes
Glucagon-like peptide-1 receptor agonists (GLP-1RA) show anti-inflammatory properties. To evaluate their clinical impact on inflammatory bowel disease (IBD) outcomes. Retrospective cohort study utilising the TriNetX database comparing IBD-specific outcomes in patients with ulcerative colitis (UC) or Crohn's disease (CD) and type 2 diabetes mellitus (T2DM) on GLP-1RA compared to oral hypoglycaemic agents. The primary outcome was hospitalisation requiring intravenous steroids and IBD-related surgery within 3 years. We performed 1:1 propensity score matching (PSM) for demographics, co-morbid conditions, BMI, laboratory values, HbA1c, and IBD medications including steroids. We identified 1130 patients in the UC GLP-1RA cohort (mean age: 58.9 ± 11.6 years, 56.3% female, 70.2% White, 57.2% with obesity) and 1140 patients in the CD GLP-1RA cohort (mean age: 56.7 ± 11.5, 61.9% female, 73.6% White, 56.2% with obesity). After PSM, there was no difference in the risk of intravenous steroid use (aHR: 1.21, 95% CI: 0.92-1.59) but a lower risk of colectomy (aHR: 0.37, 95% CI: 0.14-0.97) between the UC GLP-1RA and control cohort. There was no difference in the risk of intravenous steroid use (aHR: 1.04, 95% CI: 0.80-1.34) but a lower risk of surgery (aHR: 0.55, 95% CI: 0.36-0.84) between the CD GLP-1RA and CD control cohort. There was no difference in the risk of oral steroid use or advanced therapy initiation in the UC and CD GLP-1RA than control cohorts. We found an association between lower risk of IBD-related surgery and GLP-1RA use for T2DM in patients with UC or CD.

Metrics

1 Record Views
32 citations in Web of Science

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Gastroenterology & Hepatology
Pharmacology & Pharmacy

Expert Quote   27 May 2026

Medpage Today (Randy Dotinga)
Logo image